1 The direct cardiac electrophysiological and antifibrillatory actions of tedisamil (KC-8857) were studied in rabbit isolated hearts.
Introduction
In experimental studies and clinical trials, Class III antiarrhythmic agents have been demonstrated to be more effective than other classes of antiarrhythmic drugs in preventing lethal ventricular arrhythmias (Lynch et al., 1992; Lucchesi et al., 1993; Gilman et al., 1994) . By prolonging the ventricular effective refractory period and action potential duration, Class III antiarrhythmic agents abolish re-entrant impulses and prevent or terminate ventricular fibrillation (Sanguinetti, 1992; Uprichard & Lucchesi, 1994) . Currently available Class III drugs (amiodarone and sotalol) not only block K+ currents in the heart, but also act on other ion channels and/or receptors causing unwanted effects (Sanguinetti, 1992) . Recently developed Class III antiarrhymthmic agents, such as sematilide, MS-551, E-4031, and dofetilide (UK 68, 798) , selectively block the delayed rectifier K+ current (IK), but the reverse usedependence properties of these agents could limit their therapeutic utilily (Hondeghem & Snyders, 1990; Baskin et al., 1991; Nakaya et al., 1993; Sager et al., 1993) . Thus, the search for new compounds in this class as well as compounds targeting other types of K+ channels remains an important area of investigation.
Recent studies have shown that blockade of the transient outward current (Ito) and inward rectifier K+ current (I , both of which are involved in the repolarization of the action potential (Carmeliet, 1992a) , contribute to antiarrhythmic and antifibrillatory actions (Beatch et al., 1991; Rees & Curtis, 1993) . Tedisamil 3, .1]-nonanedihydrochloride) is a bradycardic agent and a putative Ito blocker. In rat ' Author for correspondence. isolated ventricular mycocytes, tedisamil, at low concentrations (1-20 gM), selectively suppressed IO and prolonged action potential duration (Dukes & Morad, 1989; Dukes et al., 1990) . Tedisamil had no significant effects on the inward rectifier K+ current, or inward Ca2" current in rat or guinea-pig ventricular myocytes and blocked the Na' current only at concentrations above 20 uM (Dukes & Morad, 1989; Dukes et al., 1990) . In both conscious and anaesthetized rats, tedisamil (i.v.) lengthened the ventricular effective refractory period, action potential duration, QT interval, and reduced the incidence of ventricular fibrillation induced by coronary artery ligation. In addition, tedisamil caused bradycardia and increased systemic blood pressure (Howard et al., 1989; Beatch et al., 1990; . The antifibrillatory effects and associated electrophysiological actions of tedisamil have been examined in vivo (Beatch et al., 1990; as well as in rat isolated hearts (Tsuchihashi & Curtis, 1991) , a species in which I,, is the predominant repolarization current (Josephson et al., 1984; Dukes & Morad, 1989) .
The present study explores the electrophysiological properties of tedisamil, and more importantly, demonstrates the antifibrillatory effects of tedisamil in a species possessing both functional Ito and IK in the ventricular myocardium (Giles & Imiazumi 1988; Hiraoka & Kawano, 1989; Carmeliet, 1993; de Lorenzi et al., 1994) . We used the rabbit isolated heart model in the present study to determine the direct, concentrationdependent effects of tedisamil on the ventricular effective refractory period and atrioventricular node conduction because, like the rat, the rabbit myocardium contains prominent, functional I,, and IKE In addition, the effects of tedisamil were examined in two models: prevention of hypoxia/reoxygenation/pinacidil-induced ventricular fibrillation and reversal of electrically-induced ventricular fibrillation.
Bridsh Joumal of Phamacology (1996) The hearts were equilibrated for 30 to 40 min before each experiment and perfused without recirculating the buffer. The temperature of the buffer was maintained constant at 370C. The buffer was prepared daily and adjusted to pH 7.4. The perfusion medium was circulated through an 'artificial lung' consisting of 6 metres of medical grade, gas permeable tubing (Silastic, Dow Corning Corp, Midland, MI, U.S.A.) placed in a water-heated chamber. The chamber was gassed continuously with 95% 02/5% CO2 to generate a P02 of approximately 500 mmHg in the perfusion medium. Protocol 2: Hypoxia/reoxygenation and pinacidil-induced ventricular fibrillation (Figure 1) A total of 22 rabbit isolated hearts were used in this portion of the experiment, from which 4 hearts were excluded before entering the protocol due to technical failures. Eighteen hearts were randomly allocated to three experimental groups: control, n = 6; tedisamil (1 tUM), n = 6; tedisamil (3 gM), n = 6. After 30 to 40 min of equilibration, the isolated hearts were perfused with buffer containing drug-vehicle solution (control) or tedisamil (1 gM and 3 MM) for 10 min followed by pinacidil (1.25 AM), an ATP-regulated K+ (KATP) channel opener, added to the buffer. Five min after the addition of pinacidil, the hearts were subjected to 12 min of perfusion under hypoxic conditions by changing the gas mixture in the 'artificial lung' to 95%N2/5%CO2. At the end of the hypoxic perfusion period, normoxic perfusion of the heart was reinstituted (reoxygenation) and maintained for 40 wave' of the electrogram. Hearts received a train of stimuli delivered to the region of the RVOT (S2, S3, S4-instead of a single impulse) until ventricular fibrillation occurred. Typical ventricular fibrillation induction parameters included a pulse level of 7-IV, a pulse delay of 100-150 ms, a pulse interval of 90 -100 ms, a pulse duration of 4.0 ms, and a train duration of 200-500 ms. Ventricular fibrillation was sustained for 30 s, at which time 0.3 ml of vehicle (buffer) was injected through a sideport of the aortic cannula. After an additional 30 s had elapsed, either vehicle or tedisamil (0.3 ml or 0.6 ml of 1 mM drug, or 0.3 ml of 10 mM drug) was administered. The time from the second injection to reversal to normal sinus rhythm was recorded.
Experimental protocols
Rabbit isolated atrial muscle preparation Rabbit atria (1 cm long, 3 mm wide and 2 mm thick) were excised from rabbit isolated hearts and quickly placed in oxygenated, 370C, modified Krebs-Henseleit buffer of the same composition as described in protocol 1. The muscle preparations were in contact with a pair of platinum electrodes and fixed at one end in a spring-loaded clamp. The other end of the tissue was attached to a calibrated force displacement transducer (Grass Instrument Co., Quincy MA, U.S.A., Model FT.03C). The electrical signal from the displacement transducer was amplified and recorded with a Grass Polygraph. The atrial tissue was stimulated with a Grass S88 square wave generator at a frequency of 1.5 Hz, a pulse duration of 4 ms at twice the minimum threshold voltage. The tissue was preloaded with 4 g of tension by adjusting the height of the force displacement transducer.
The isolated muscle preparations were allowed to equilibrate for 60 min under normoxia (95% 02/5% C02) or 20 min under hypoxia (95% N2/5% CO2) followed by 40 min reoxygenation (n= 10 in each group), during which time the bathing media was replaced three times. The experimental protocol was begun after a steady state of isometric force development had been achieved. The concentration-response relationship for the negative inotropic action of pinacidil was established by a cumulative increase in the concentration of pinacidil in the bathing media. There was a 5 min interval between each increment in drug concentration to allow a new steady state response to develop. To determine if tedisamil could reverse pinacidil-induced negative inotropy, tedisamil (3 gM) was added to the bathing media after the final concentration of pinacidil had been achieved in the bath. Thereafter, the recovery of muscle tension was monitored for 5 min. The change in isometric tension was determined and expressed as a percentage of the pre-drug, baseline value.
Materials
Tedisamil hydrochloride (KC-8857; 3,7-di-(cyclopropylmethyl) -9,9 -tetramethylene -3,7-diazabicyclo[3.3. l]nonane dihydrochloride, Figure 2 ) was supplied by Solvay Pharma-
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Figure 2 Chemical structure of tedisamil (KC-8857) (3,7-di-(cyclopropylmethyl)-9,9-tetramethylene-3,7-diazabicyclo[3.3. lInonane dihydrochloride). ceuticals (Germany). All other materials were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.) unless otherwise specified.
Data analysis
The data are expressed as mean + s.e. mean. The difference in the incidence of ventricular fibrillation among groups was analyzed by Fisher's Exact test. ANOVA (factorial) was used for comparisons between groups at specific time points. AN-OVA (repeated measures), followed by a Fisher's protected least significant difference (PSLD) post hoc test was used for comparisons over time within groups. Statistical significance was established as a probability of <0.05.
Results
Electrophysiological action of tedisamil 
Prevention of ventricular fibrillation
One group of hearts was used as a control group while the other two groups were exposed to 1 gM or 3 Mm tedisamil added to the perfusion medium 10 min before the addition of pinacidil. There was a high incidence of ventricular fibrillation during hypoxia and reoxygenation in both the control group and in the group of hearts treated with 1 gM tedisamil (5/6 and 4/6, respectively). When the concentration of tedisamil was increased to 3 gM, the incidence of ventricular fibrillation was reduced significantly (0/6, P= 0.007 vs. control group, by Fisher's Exact Test; Figure 6 and Table 1 ). Figure 6 shows the time course of occurrence of ventricular fibrillation in all groups. Time (min) Figure 6 Time course of development of ventricular fibrillation in the hypoxic/reoxygenated rabbit isolated heart. Three groups of hearts (n=6 in each group) were perfused with buffer containing pinacidil (1.25pM) for 5min, then subjected to hypoxia for 12min followed by 40min of reoxygenation. Two groups of hearts were exposed to tedisamil (1 and 3yM) 10min before the addition of pinacidil in the perfusion medium. Ventricular fibrillation occurred in 5 of 6 hearts from the control group (without tedisamil). Tedisamil, at 3Mm, significantly reduced the incidence of ventricular fibrillation compared with that of the control group. Each symbol represents an individual isolated heart. Figure 8 is a representative tracing from a heart that was successfully defibrillated after the administration of tedisamil.
Effects of tedisamil on cardiac function
During the study of antifibrillatory effects in the three groups of hearts (Protocol 2), the cardiac function was monitored Figure 7 Time course for chemical defibrillation by tedisamil of electrically-induced ventricular fibrillation in the rabbit isolated heart. Ventricular fibrillation (VF) was induced in two sets of hearts (at a) one of which received a bolus injection of vehicle 30 (b) and 60 s (c) after induction of VF (n=4). The other group of hearts received a bolus injection of vehicle 30s (b) after induction of VF and 0.3 ml of 10mM tedisamil 60s (c) after induction of VF. Hearts receiving vehicle only did not revert to normal sinus rhythm whereas 100% of hearts receiving tedisamil were converted to normal sinus rhythm (P = 0.008 compared to vehicle by Fisher's Exact Test).
continuously. All hearts were paced electrically from the right atrium at a frequency of 20-30% above the intrinsic sinus rate. Heart rate is expressed as the total number of ventricular complexes and includes both the paced ventricular complexes as well as those depolarizations arising spontaneously. During the latter phase of hypoxia the heart rate was reduced in each of three groups even though atrial electrical pacing was maintained. The observed bradycardia suggests the development of atrioventricular block due to hypoxia. Hearts treated with 1 gM tedisamil demonstrated less bradycardia during hypoxia, compared to 3 gM tedisamil-treated hearts (Table 2) . Normal atrioventricular conduction returned upon reoxygenation in all groups. There was no difference in heart rate among groups at respective time-points throughout the experimental procedure (Table 2) .
Tedisamil, in a concentration-dependent manner, increased the coronary perfusion pressure (CPP) from a mean baseline value of 43+3 mmHg to 54+4 mmHg at 1 gM and from 37 + 3 mmHg to 50 + 3 mmHg at 3 gIM after 10 min of exposure (Table 2) . Both LVDP and + dP/dt decreased to the same extent during hypoxia followed by a partial return upon reoxygenation in all experimental groups. Due to the development of ventricular fibrillation, very few hearts remained in the control group and 1 gM tedisamil-treated groups during reoxygenation, thus precluding statistical analysis of the data towards the latter part of the reoxygenated period. Tedisamil did not change any cardiac functional parameters, such as LVDP, left ventricular end-diastolic pressure (LVEDP) and left ventricular + dP/dt throughout the experiment (Tables 3  and 4 ).
Rabbit isolated atrial muscle
Reversal of the pinacidil-induced negative inotropic effect The amplitude of isometric contractile force was approximately 62% of baseline after exposure to the final concentration of pinacidil (10'-M) in atrial tissue equilibrated under normoxia.
The subsequent addition of tedisamil (3 gM) to the bathing medium in the continued presence of pinacidil (10-4 M) resulted in a reversal of the pinacidil-induced negative inotropic action. The isometric-contractile force of the atrial muscle preparations recovered and achieved 86% of pre-drug baseline values after 5 min of 3 gM tedisamil exposure (Figure 9a) . Similarly, contractile force in atrial tissue was approximately 67% of baseline after treatment with the final concentration of pinacidil in atrial tissue equilibrated under hypoxia/reoxygenation. The isometric-contractile force of the atrial muscle recovered to approximtely 86% of baseline contractions after treatment with 3 gM tedisamil (Figure 9b Figure 8 An example of the chemical defibrillatory effects of tedisamil in the rabbit isolated heart. Sustained ventricular fibrillation (VF) was elicited by a train of electrical stimuli applied to the RVOT. Tedisamil (0.3ml of 10mM) was administered to the heart through the cannulated aorta while the coronary vessels were perfused continuously with oxygenated buffer. The cycle length of the fibrillatory waves was prolonged progressively and ventricular fibrillation was converted to normal sinus rhythm after 1 min and 50s exposure to tedisamil. Cardiac function recovered to the prefibrillation state 13min after drug administration.
Discussion
Unlike calcium channel blockers and f-adrenoceptor antagonists, tedisamil does not depress ventricular contractile function while reducing heart rate (Thormann et al., 1993) . The blockade of K+ outward currents and subsequent prolongation of repolarization in the sinoatrial pacemaker cells accounts for the bradycardic action of tedisamil (Dukes & Morad, 1992) . The extent of QTc prolongation caused by tedisamil has been shown to be species-dependent. Tedisamil caused a significant increase in the QTc and/or prolongation of the action potential duration in rat myocardium (Beatch et al., 1990) . In contrast, limited QTc prolongation was observed in other species, such as dogs, guinea-pigs, rabbits, and pigs (Buschmann et al., 1989) . This difference may be due to the role of different K+ channels in repolarization of the cardiac tissue in a variety of species. The antiarrhythmic and antifibrillatory effects of tedisamil have been reported mainly in rat heart models (Beatch et al., 1991; Adaikan et al., 1992; Bril et al., 1993) , a species in which It. is the predominant outward repolarizing current in ventricular myocardium. In our investigation, the direct electrophysiological and antifibrillatory effects of tedisamil were investigated in rabbit isolated hearts. Two independent models were used to assess the antifibrillatory action of tedisamil. In conscious and anaesthetized rats, Adaikan et al. (1992) and Beatch et al. (1991) reported that tedisamil (0.5-4 mg kg-', i.v.) dose-dependently lengthened the effective refractory period, the duration of epicardial intracellular action potential, and the QTc interval. Bril et al. (1993) reported a similar observation and suggested that specific blockade of Ito was responsible for the apparent Class III action of tedisamil, since the IKr (rapidly activating component of IK) blocker, E-4031, did not change QTc interval in a similar anaesthetized rat model. Tedisamil was also shown to prolong the effective refractory period and QTc interval in anaesthetized dogs (Wallace et al., 1995) . In our investigation, the blockade of both It. and IK by tedisamil may be operative and responsible for the observed increases in the ventricular refractory period (Figure   4 ). Values in parentheses represent numbers of hearts from which mean ± s.e. were calculated. tPinacidil concentration= 1.25 gM. Table 4 Effects of tedisamil on left ventricular pressure +dp/dt in rabbit isolated hearts + dp/dt (2) 200 (1) 455 + 73 (5) When rabbit isolated hearts were perfused in the presence of pinacidil, a high incidence of spontaneous and sustained ventricular fibrillation occurred during hypoxic perfusion or during reoxygenation, which was significantly reduced in the presence of 3,M tedisamil ( Figure 6 ). Shortening of action potential duration, reduction of refractory period and initiation of re-entry are precursors to the onset of ventricular fibrillation Fagbemi et al., 1993) . Several K+ channel blockers, such as glibenclamide, E-403 1, clofilium (Friedrichs et al., 1994) and ibutilide , effectively prevented the development of ventricular fibrillation in this model. In vivo studies reveal that tedisamil prevents regional ischaemia-and reperfusion-induced ventricular fibrillation in anaesthetized and conscious rats (Beatch et al., 1991; Adaikan et al., 1992; Bril et al., 1993 (6) 37±7 (6) ventricular fibrillation could not occur (Adaikan et al., 1992) . In rat isolated hearts, the antifibrillatory effect of tedisamil was limited to reducing the duration of ventricular fibrillation and had no influence on the incidence of ventricular fibrillation elicited by regional ischaemia and reperfusion (Tsuchihashi & Curtis, 1991 (1993) who observed that the combination of tedisamil with E-4031 in the anaesthetized rat exerted a greater antifibrillatory effect than with tedisamil alone. The inhibition of the ATP-regulated potassium channel may contribute to the antifibrillatory action of tedisamil in the pinacidil-treated hypoxic/reoxygenated heart. In the present experimental model, activation of the KATP channel by pinacidil serves an important role in the initiation of ventricular fibrillation Fagbemi et al., 1993) . Pinacidil selectively enhances the KATP current (Arena & Kass, 1989) and shortens the action potential duration, thus facilitating reentry in myocardial tissue (Di Diego & Antzelevitch, 1993; Coromilas et al., 1994) . Hypoxia and reoxygenation lead to the development of an appropriate substrate for re-entrant arrhythmias facilitated further by a decrease in myocardial cellular ATP content which potentiates the action of pinacidil on the ventricular ATP-regulated potassium channel . Inside-out patch clamp studies from rat ventricular cells demonstrate that tedisamil (20 gM) significantly decreased KATP channel activity (Faivre & Bril, 1992) . Bril et al. (1993) observed that tedisamil and E-4031 increased the QTc more during ischaemia than during the pre-ischaemic period, suggesting that tedisamil and E-4031 may have an effect on a current involved during acute ischaemia, such as the KATP current. The ability of tedisamil to reverse the pinacidil-induced negative inotropic effect in rabbit isolated atrial tissue further supports our hypothesis that tedisamil inhibits the KATP channel in myocardial tissue (Figure 9 ).
The chemical defibrillatory effect of tedisamil was demonstrated in non-ischaemic rabbit isolated hearts in which ventricular fibrillation was induced by electrical stimulation (Figure 7 ). Tedisamil restored normal sinus rhythm under conditions in which the myocardial tissue was perfused under normoxic conditions. Thus, one would assume that cellular ATP content was normal and that the KATp-dependent channel would be closed (Kakei et al., 1985) . Our observation is consistent with the ability of tedisamil to terminate ventricular fibrillation in rat isolated hearts (Tsuchihashi & Curtis, 1991) .
In the latter studies, tedisamil (3 gM) reduced the duration of VF in regional ischaemic/reperfused hearts, but was unable to prevent the induction of VF. Chemical defibrillation in this model had been observed with other compounds possessing Class III activity . The mode and kinetics of action of tedisamil in the conversion of VF is different from that of ibutilide and clofilium. The frequency of the fibrillatory waves decreased immediately upon exposure of the heart to tedisamil and slowed progressively over time until VF was converted to normal sinus rhythm. The antiarrhythmic action of tedisamil in the normoxic heart may be related to its ability to inhibit the two potassium currents responsible for cardiac action potential repolarization under normoxic conditions, i.e. the transient outward current (Ito) (Dukes & Morad, 1989) and the delayed rectifier current (IK) (Dukes et al., 1990) . ATP-regulated potassium channels are present in cardiac muscle cells (Noma, 1993) , and would be closed and non-functional under conditions of normoxic perfusion thus making unimportant any action of tedisamil upon the IKAw,_ However, we cannot exclude the possibility that partial sodium block by tedisamil might also contribute to threshold elevation, thereby slowing intramyocardial conduction. In contrast to other studies, tedisamil at 3 gM significantly increased the ventricular excitation threshold and prolonged the P-R interval at 1, 3 and 10 gM, suggesting an action of the drug upon other ion channels (Figure 4b and c) . There have been reports of sodium channel modulation by tedisamil. In single rat ventricular myocytes, the suppression of the sodium current by tedisamil occurred only at a concentration greater than 20 uM (Dukes & Morad, 1989; Dukes et al., 1990) .
Both positive and negative inotropic actions of tedisamil have been reported in in vivo and in vitro investigations as well as an improvement in cardiac function during myocardial ischaemia. These effects of tedisamil on cardiac function, however, were attributed primarily to its bradycardic action and subsequent favourable influence on the oxygen supply/ demand balance in the ischaemic hearts (Grohs et al., 1989; Duchosal & Opie, 1992; Raberger et al., 1992) . The bradycardic effect of tedisamil (under normoxia) was not observed in our investigation since the heart was paced throughout the experimental protocol (Table 2) . Therefore, the antifibrillatory effect of tedisamil is due to its direct electrophysiological action, independent of any influence on the cardiac function and/ or the extent of pathophysiological conditions. An increase in arterial resistance has been observed with other K+ channel antagonists. Studies (Bray & Quast, 1992; Kreye et al., 1992) indicate that tedisamil and glibenclamide directly modulate mechanical tension in rat and rabbit isolated vascular smooth muscle by affecting K+ channels. An increase of blood pressure or vascular resistance has been observed with tedisamil experimentally in vivo as well as clinically (Beatch et al., 1991; Mitrovic et al., 1992; Thormann et al., 1993 ).
In conclusion, tedisamil possesses an effective antifibrillatory and chemical defibrillatory action in two experimental models. The effects are independent of its potential bradycardic action and influence on cardiac function. The Class III antiarrhythmic activity, i.e., increase of refractoriness, and prevention and/or termination of re-entry appear to be the primary mechanisms for its antifibrillatory effects, although effects on the other channels including sodium and calcium cannot be entirely excluded. The nature of the experimental model indicates that blockade of the ATP-regulated potassium channel is important in mediating the electrophysiologic effects of tedisamil. However, the inhibition of the I,. and the Ik may likewise contribute to the beneficial effects. Tedisamil may be unique when compared to other Class III antiarrhythmic agents (E-4031 (Sanguinetti & Jurkiewicz, 1990 ) and Dofetilide (Carmeliet, 1992b) ) that selectively block IKr current. Additional studies in more elaborate in vivo models are needed to determine fully its potential in the prevention of lethal arrhythmias.
